99% Purity Antineoplastic Drug Axitinib for Advanced Kidney Cancer

99% Purity Antineoplastic drug Axitinib CAS 319460-85-0
Quick Details of Axitinib:
Product Name:Axitinib
CAS:319460-85-0
Synonyms:Axitinib (usan);D03218;Axitinib(AG 013736);Axtinib;N-Methyl-2-({3-[(E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzaMide;Inlyta;10mg;Axitinib (TINIBS)
Molecular Formula:C22H18N4OS
Molecular Weight:386.47
Melting point:213-215°C
Appearance:White Powder
Density:1.4
Storage:-20°C Freezer
Standard:Enterprise Standard


Product Description
1.Axitinib is also called by its brand name Inlyta. It is a type of drug called a tyrosine kinase inhibitor, which is a cancer growth blocker. It blocks certain proteins called tyrosine kinases from acting on cells. Tyrosine kinases signal to cancer cells to grow.Axitinib blocks different types of tyrosine kinase and is called a multi kinase inhibitor
It stops cancer cells forming blood vessels, which the cancer needs in order to grow. This is called anti angiogenesis treatment.Axitinib is a treatment for advanced kidney cancer. You may also have it as part of a clinical trial for other cancers including soft tissue sarcoma and thyroid cancer.


2.Axitinib interferes with the growth of some cancer cells.Axitinib is used to treat advanced kidney cancer.Axitinib is usually given after other cancer medicine has been tried without success.
Axitinib may also be used for purposes not listed in this medication guide.Axitinib dose-dependently inhibits tumor growth in MV522 with ED50 value of 8.8 mg/kg twice daily, based on the relationship between dose and the corresponding TGI (tumor growth inhibition).


3.Axitinib is an oral tyrosine kinase inhibitor selective for vascular endothelial  (VEGF) receptors -1, -2 and -3 that is used in the therapy of advanced renal cell carcinoma.  Axitinib therapy is commonly associated with transient elevations in serum aminotransferase that are generally mild and asymptomatic.  Axitinib has yet to be linked to instances of clinically apparent acute liver injury.
 


Applications:
Axitinib is indicated for kidney cancer. Axitinib is a kinase inhibitor shown to inhibit the vascular endothelial receptors (VEGFR-1, VEGFR-2, and VEGFR-3) implicated in angiogenesis and tumor growth leading to cancer progression.Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value


Our factory and workshop





 Commerce Clause
 
 
 
 
 
 
 
  99% Purity Antineoplastic drug Axitinib CAS 319460-85-0
Quick Details of Axitinib:
Product Name:Axitinib
CAS:319460-85-0
Synonyms:Axitinib (usan);D03218;Axitinib(AG 013736);Axtinib;N-Methyl-2-({3-[(E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzaMide;Inlyta;10mg;Axitinib (TINIBS)
Molecular Formula:C22H18N4OS
Molecular Weight:386.47
Melting point:213-215°C
Appearance:White Powder
Density:1.4
Storage:-20°C Freezer
Standard:Enterprise Standard


Product Description
1.Axitinib is also called by its brand name Inlyta. It is a type of drug called a tyrosine kinase inhibitor, which is a cancer growth blocker. It blocks certain proteins called tyrosine kinases from acting on cells. Tyrosine kinases signal to cancer cells to grow.Axitinib blocks different types of tyrosine kinase and is called a multi kinase inhibitor
It stops cancer cells forming blood vessels, which the cancer needs in order to grow. This is called anti angiogenesis treatment.Axitinib is a treatment for advanced kidney cancer. You may also have it as part of a clinical trial for other cancers including soft tissue sarcoma and thyroid cancer.


2.Axitinib interferes with the growth of some cancer cells.Axitinib is used to treat advanced kidney cancer.Axitinib is usually given after other cancer medicine has been tried without success.
Axitinib may also be used for purposes not listed in this medication guide.Axitinib dose-dependently inhibits tumor growth in MV522 with ED50 value of 8.8 mg/kg twice daily, based on the relationship between dose and the corresponding TGI (tumor growth inhibition).


3.Axitinib is an oral tyrosine kinase inhibitor selective for vascular endothelial  (VEGF) receptors -1, -2 and -3 that is used in the therapy of advanced renal cell carcinoma.  Axitinib therapy is commonly associated with transient elevations in serum aminotransferase that are generally mild and asymptomatic.  Axitinib has yet to be linked to instances of clinically apparent acute liver injury.
 


Applications:
Axitinib is indicated for kidney cancer. Axitinib is a kinase inhibitor shown to inhibit the vascular endothelial receptors (VEGFR-1, VEGFR-2, and VEGFR-3) implicated in angiogenesis and tumor growth leading to cancer progression.Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value


Our factory and workshop





 Commerce Clause
 
 
 
 
 
 
 
 

Oxygen&Water Jet Peel

Oxygen Facial Fda,Oxygen Facial Machine,Oxygen Jet Peel,Oxygen Jet Peel Machine

Body Firming Machine,Physiotherapy Machines Co., Ltd. , http://www.ipl-hair-removals.com